[go: up one dir, main page]

UY28334A1 - Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. - Google Patents

Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.

Info

Publication number
UY28334A1
UY28334A1 UY28334A UY28334A UY28334A1 UY 28334 A1 UY28334 A1 UY 28334A1 UY 28334 A UY28334 A UY 28334A UY 28334 A UY28334 A UY 28334A UY 28334 A1 UY28334 A1 UY 28334A1
Authority
UY
Uruguay
Prior art keywords
pure
antistrogens
prophylaxis
treatment
composition
Prior art date
Application number
UY28334A
Other languages
English (en)
Inventor
Gerhard Siemeister
Ulrike Fuhrmann
Jens Hoffmann
Martin Schneider
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33450989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28334(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY28334A1 publication Critical patent/UY28334A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos y usos para prevenir o tratar enfermedades pendientes de hormonas, en particular cáncer de mama,en un mamífero, mediante una combinación de un antagonista de receptores de progesterona, en particular el antagonista de receptores de progesterona 11B-(4-acetilfenil) -17B-hidroxi-17a- (1,1,2,2,2-pentafluoroetil) -estra -4, 9-dien-3-ona o un derivado o análogo del mismo aceptable para uso farmacéutico, y un antiestrógeno puro, en particular un compuesto de la fórmula general I, definida en la memoria descriptiva, p. ej. 11B-fluoro-17a-metil-7a-(5-(metil(8,8,9,9,9-pentafluorononil)amino)pentil)-estra-1,3,5 (10)-trien-3,17B-diol. La invención se relaciona además con composiciones farmacéuticas que comprenden dicha combinación.
UY28334A 2003-05-28 2004-05-27 Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. UY28334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/446,165 US20040242551A1 (en) 2003-05-28 2003-05-28 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Publications (1)

Publication Number Publication Date
UY28334A1 true UY28334A1 (es) 2004-12-31

Family

ID=33450989

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28334A UY28334A1 (es) 2003-05-28 2004-05-27 Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.

Country Status (18)

Country Link
US (3) US20040242551A1 (es)
EP (2) EP1628669A1 (es)
JP (1) JP2006528226A (es)
KR (1) KR20060005412A (es)
CN (1) CN1893955A (es)
AR (1) AR044450A1 (es)
AU (1) AU2004243500A1 (es)
BR (1) BRPI0410707A (es)
CA (1) CA2524750A1 (es)
CL (1) CL2004001317A1 (es)
EA (1) EA011506B1 (es)
MX (1) MXPA05012841A (es)
NO (1) NO20056153L (es)
PE (1) PE20050207A1 (es)
TW (1) TW200505936A (es)
UY (1) UY28334A1 (es)
WO (1) WO2004105768A1 (es)
ZA (1) ZA200510449B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
US20070276017A1 (en) * 2003-06-10 2007-11-29 Chikara Murakata Thiadiazoline Derivative
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
KR102198059B1 (ko) * 2013-04-11 2021-01-05 바이엘 파마 악티엔게젤샤프트 프로게스테론 수용체 길항제 투여 형태
CN115505019B (zh) * 2022-11-07 2024-01-26 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA931944A (en) * 1970-04-24 1973-08-14 Anner Georg Oestrogenically highly active steroids and process for their manufacture
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE19622457A1 (de) * 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
DE19807791A1 (de) * 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
EP1326617B9 (en) * 2000-10-18 2006-10-25 Schering Aktiengesellschaft Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma
IL154975A0 (en) * 2000-10-18 2003-10-31 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
BRPI0410707A (pt) 2006-06-13
WO2004105768A1 (en) 2004-12-09
EP1834644A3 (en) 2007-11-07
TW200505936A (en) 2005-02-16
US20050014736A1 (en) 2005-01-20
WO2004105768A8 (en) 2006-04-06
EP1628669A1 (en) 2006-03-01
ZA200510449B (en) 2007-04-25
NO20056153L (no) 2006-02-22
CA2524750A1 (en) 2004-12-09
CL2004001317A1 (es) 2005-05-06
US20070238714A1 (en) 2007-10-11
AR044450A1 (es) 2005-09-14
MXPA05012841A (es) 2006-02-13
CN1893955A (zh) 2007-01-10
US20040242551A1 (en) 2004-12-02
AU2004243500A1 (en) 2004-12-09
EP1834644A2 (en) 2007-09-19
EA200501739A1 (ru) 2006-06-30
PE20050207A1 (es) 2005-04-28
JP2006528226A (ja) 2006-12-14
EA011506B1 (ru) 2009-04-28
KR20060005412A (ko) 2006-01-17

Similar Documents

Publication Publication Date Title
BRPI0516243C1 (pt) uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
ECSP055576A (es) Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas
EE200300155A (et) Antiprogestiinide kasutamine hormoonsõltuvate haiguste profülaktikaks ja raviks
PE20060485A1 (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
IS2702B (is) Notkun á (11beta, 17beta)-11-(1,3-bensódíoxól-5-ýl)-17-hýdroxý-17-(1-própýnýl)-estra-4,9-díen-3-ón í meðhöndluninni á alvarlegri geðdeyfðartruflun
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
AR066231A1 (es) Combinacion de antagonista del receptor de progesterona con atiestrogenos no esteroidales para usar en enfermedades mediadas por brca (genes supresores de tumores)
RU2325160C1 (ru) Средство для лечения рака предстательной железы и профилактики его рецидива
AR066232A1 (es) Combinacion de antagonista del receptor de progesterona con un inhibidor de la aromatasa para usar en enfermedades mediadas por brca (genes supresores de tumores)
CL2008001148A1 (es) Combinacion farmaceutica que comprende un antagonista del receptor de progesterona 11beta-(4-acetilfenil)-17beta-hidroxi-17alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno; y su uso para el tratameinto del cancer de mama.
AR032371A1 (es) Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
AR044095A1 (es) Composicion farmaceutica que comprende un antagonista del receptor de la hormona del crecimiento y un antihipertensivo y uso de los mismos para prepararla
TH76790A (th) สารผสมซึ่งประกอบรวมด้วยโปรเจสเทอโรน-รีเซพเตอร์ แอนทาโกนิสท์ และแอนติเอสโทรเจ็นบริสุทธิ์ สำหรับการป้องกันโรค และการบำบัดโรคที่ต้องพึ่งพาฮอร์โมน
AR036257A1 (es) Sulfamatos de 2-alcoxiestradiol de accion antitumoral
PE20091020A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa
TW200733955A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
DOP2005000278A (es) Composiciones farmaceuticas solidas que comprenden una combinacion de drospirenon, etinilestradiol y un agente surfactante adecuado que presentan una homogeneidad de contend y velocidad de dosolucion asegurada para la droga no micronizada, procedomiento para prepara dicha composicion y uso de esta composicion para preparar un medicamento.
UY29227A1 (es) Composiciones farmacéuticas sólidas que comprenden una combinación de drospirenona, etinilestradiol y un agente surfactante adecuado que presentan una homogeneidad de contenido y velocidad de disolución asegurada para la droga no micronizada, procedi

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150522